Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of NX-13 in Healthy Volunteers
NCT04458805Phase 1Completed
- Sponsor
- Landos Biopharma, Inc.
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ulcerative colitis (UC) comparing NX-13 with Placebo (2 arms). Primary endpoints: Incidence, severity and relationship of adverse events, Incidence of abnormal Physical examination findings and 4 more. Started Jul 2020; status: completed.
02
Drugs
amelenodor
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04458805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04458805.